Evommune Discontinues Eczema Candidate EVO756; Focus Shifts to EVO301
Evommune (NYSE:EVMN) announced on September 8, 2026 that its eczema candidate EVO756 failed in a Phase 2b trial. The drug did not meet primary or secondary endpoints for treating moderate-to-severe atopic dermatitis and will no longer be developed for this indication. This follows an earlier discontinuation of the compound for chronic spontaneous urticaria after a June failure, leaving migraine prevention as its only remaining development path. The company is now placing greater emphasis on EVO301, which showed promising results in a Phase 2a trial with a significant reduction in eczema severity compared to placebo. A larger Phase 2b study for EVO301 is planned for mid-2027 and could be pivotal for the company's future. Evommune also has strong financial resources, reporting $288 million in cash as of June 30, which should support operations through at least 2029. Despite these positives, EVO301 faces challenges transitioning from intravenous to subcutaneous dosing and must demonstrate consistent safety and efficacy across a larger population. Meanwhile, the company's R&D expenses have increased significantly in Q2 compared to last year, raising concerns about future financing needs.
Tickers: $EVMN
Topics: biotech drug_pipeline eczema pharma